文献速递血栓与止血

静脉血栓栓塞症患者围手术期中断直接口服抗凝药后的血栓与出血结局

Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.
PubMed 文献 · J Thromb Haemost · 2017-04-03

本研究回顾性分析了190例因静脉血栓栓塞症(VTE)服用直接口服抗凝药(DOAC)并因侵入性操作需暂时中断抗凝的连续患者。30天症状性VTE发生率为1.05%(95%CI 0.29-3.8%),30天大出血发生率为0.53%(95%CI 0.09-2.93%),无死亡。基于DOAC半衰期和操作相关出血风险的停药方案似乎是安全有效的。

要点

  • 190例既往VTE患者围手术期中断DOAC,30天VTE发生率1.05%,大出血发生率0.53%。
  • 30天随访期间无死亡,临床相关非大出血发生率为3.16%。
  • 基于DOAC半衰期和操作出血风险的停药方案似乎安全有效。

核心结论

  • 在VTE患者中,采用考虑DOAC半衰期和操作相关出血风险的策略进行围手术期中断,似乎是安全有效的。

研究设计与样本

  • 回顾性分析连续服用DOAC因既往VTE需暂时中断抗凝以进行侵入性操作的患者,共纳入190例。

主要发现

  • 30天症状性VTE发生率为1.05%(95%CI 0.29-3.8%)。
  • 30天大出血发生率为0.53%(95%CI 0.09-2.93%)。
  • 30天随访期间无死亡。
  • 临床相关非大出血发生率为3.16%(95%CI 1.46-6.72%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Studies evaluating the procedural interruption of direct oral anticoagulants (DOACs) are lacking. We conducted a study of the interruption of DOACs for prior venous thromboembolic disease (VTE). The post-operative risks of recurrent VTE and major bleeding are low in this patient population. A scheme based on half-life and procedure-related bleeding appears safe and efficacious. SUMMARY: Background Direct oral anticoagulants (DOACs) are increasingly being used in the setting of venous thromboembolic disease (VTE). There is little evidence to guide the peri-procedural interruption of DOACs in this patient population. A number of studies have evaluated the perioperative interruption of DOACs based on half-life of the anticoagulant and the underlying procedural bleeding risk in patient with atrial fibrillation, but it remains unclear whether these findings can be extended to patients with VTE. Objective Evaluate thrombotic and bleeding outcomes following the perioperative interruption of direct oral anticoagulation in patients with prior VTE. Methods We conducted a retrospective analysis of consecutive patients on a DOAC for prior VTE requiring temporary interruption of anticoagulation for an invasive procedure. The primary efficacy outcome was the 30-day symptomatic VTE rate, and the primary safety outcome was the 30-day major bleeding rate. Secondary outcomes included overall mortality and the rate of clinically relevant non-major bleeding. Results A total of 190 patients were included in the analysis. The 30-day VTE rate was 1.05% (95% CI, 0.29-3.8%) and the 30-day major bleeding rate was 0.53% (95% CI, 0.09-2.93%). There were no deaths during the 30-day follow-up period. The rate of clinically relevant non-major bleeding was 3.16% (95%CI , 1.46-6.72%). Conclusions The perioperative interruption of DOACs in the setting of VTE, using a strategy that considers the half-life of the DOAC and the underlying procedural bleeding risk, appears to be both safe and effective.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Shaw J, de Wit C, Le Gal G, et al. Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease. J Thromb Haemost. 2017. PMID: 28296069. doi:10.1111/jth.13670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。